Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
664 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2017-05-09)
Due Date
May 09, 2027
Grace Period Ends
November 09, 2027
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Oct 3, 2023 | 8.PR | O | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED |
| Oct 3, 2023 | NAS8 | E | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED |
| Oct 2, 2023 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED |
| Sep 19, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Sep 19, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Sep 19, 2023 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Sep 19, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Sep 6, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Sep 6, 2023 | PRA8 | O | POST REGISTRATION ACTION MAILED - SEC. 8 |
| Apr 11, 2023 | ES8R | I | TEAS SECTION 8 RECEIVED |
| May 9, 2022 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Dec 17, 2018 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Dec 17, 2018 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| May 9, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Apr 5, 2017 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Apr 4, 2017 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Mar 14, 2017 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Mar 6, 2017 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Mar 6, 2017 | IUAF | S | USE AMENDMENT FILED |
| Jan 11, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jan 10, 2017 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Dec 16, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Dec 16, 2016 | IROA | I | RESPONSE TO ITU OFFICE ACTION ENTERED |
| Dec 13, 2016 | INCE | O | ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST |
| Nov 29, 2016 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 29, 2016 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jul 6, 2016 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 6, 2016 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Apr 28, 2016 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 27, 2016 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Apr 12, 2016 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 12, 2016 | EXT3 | S | SOU EXTENSION 3 FILED |
| Dec 3, 2015 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Dec 2, 2015 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Nov 20, 2015 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 20, 2015 | EXT2 | S | SOU EXTENSION 2 FILED |
| Jun 19, 2015 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jun 18, 2015 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 18, 2015 | EX1G | S | SOU EXTENSION 1 GRANTED |
| May 20, 2015 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 20, 2015 | EXT1 | S | SOU EXTENSION 1 FILED |
| Dec 2, 2014 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Oct 7, 2014 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 7, 2014 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 17, 2014 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Sep 2, 2014 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Aug 29, 2014 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 29, 2014 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 29, 2014 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 26, 2014 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Detailed Classifications
Class 041
[ Education and healthcare educational services, namely, providing training and programs concerning awareness and consequence of hemolysis, the risk of hemolysis occurring in certain patients receiving immunoglobulin infusion therapy and the identification and treatment with intravenous immunoglobulin therapy of patients in whom hemolysis may develop ]
First Use Anywhere:
Jul 31, 2016
First Use in Commerce:
Jul 31, 2016
Class 044
Providing medical and pharmaceutical information to patients and healthcare practitioners, namely, providing medical information regarding hemolysis and the risk of occurrence in and the treatment of certain patients undergoing human intravenous immunoglobulin therapy and providing information relating to the therapeutic properties of pharmaceuticals for the treatment of hemolysis
First Use Anywhere:
Jul 31, 2016
First Use in Commerce:
Jul 31, 2016
Classification
International Classes
041
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"IG"
USPTO Documents
Loading USPTO documents...